CompletedNot Applicable

Impact of NR3C1 rs41423247 (BclI) Polymorphism on Disease Severity in Alopecia Areata

Egypt120 participantsStarted 2023-11-01

Plain-language summary

Alopecia areata is an autoimmune, non-scarring hair loss disorder with multifactorial pathogenesis. The glucocorticoid receptor gene (NR3C1) plays an essential role in immune regulation and inflammatory response. The rs41423247 polymorphism (BclI) may influence glucocorticoid sensitivity and disease activity. This study aims to investigate the association between NR3C1 rs41423247 polymorphism and susceptibility to alopecia areata and to evaluate its correlation with disease severity using the Severity of Alopecia Tool (SALT) score.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria (Cases): * Clinically diagnosed alopecia areata * Age ≥ 18 years * Both sexes * Willingness to participate and provide informed consent Inclusion Criteria (Controls): * Apparently healthy individuals * No history of autoimmune disease * Age- and sex-matched to cases * Provided informed consent Exclusion Criteria: * Presence of other autoimmune or inflammatory diseases * Current systemic immunosuppressive therapy * Pregnancy or lactation * Refusal to participate

What they're measuring

Distribution of NR3C1 rs41423247 Genotypes and Alleles

Timeframe: Baseline

Trial details

NCT IDNCT07455708

SponsorBenha University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-11-01

View on ClinicalTrials.gov More Alopecia Areata(AA) trials